thalidomide has been researched along with Allergic Alveolitis, Extrinsic in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 64-year-old man with recurrent multiple myeloma (BJP-κ type) was treated with 15 mg of lenalidomide (LEN) and dexamethasone." | 8.93 | Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma. ( Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C, 2016) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 7.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| "A 64-year-old man with recurrent multiple myeloma (BJP-κ type) was treated with 15 mg of lenalidomide (LEN) and dexamethasone." | 4.93 | Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma. ( Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C, 2016) |
| "Lenalidomide is a new immunomodulatory drug, FDA-approved for the treatment of the 5q-myelodysplastic syndrome and refractory or relapsed multiple myeloma (MM)." | 3.76 | A case of lenalidomide-induced hypersensitivity pneumonitis. ( Feilchenfeldt, J; Györik, S; Lerch, E; Mazzucchelli, L; Quadri, F, 2010) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 3.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatsuse, M | 1 |
| Odaira, E | 1 |
| Fuchida, SI | 1 |
| Okano, A | 1 |
| Murakami, S | 1 |
| Shimazaki, C | 1 |
| Kortuem, M | 1 |
| Einsele, H | 1 |
| Lerch, E | 1 |
| Györik, S | 1 |
| Feilchenfeldt, J | 1 |
| Mazzucchelli, L | 1 |
| Quadri, F | 1 |
| Thornburg, A | 1 |
| Abonour, R | 1 |
| Smith, P | 1 |
| Knox, K | 1 |
| Twigg, HL | 1 |
1 review available for thalidomide and Allergic Alveolitis, Extrinsic
| Article | Year |
|---|---|
Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.
Topics: Alveolitis, Extrinsic Allergic; Angioedema; Angiogenesis Inhibitors; Humans; Lenalidomide; Male; Mid | 2016 |
3 other studies available for thalidomide and Allergic Alveolitis, Extrinsic
| Article | Year |
|---|---|
Lenalidomide-induced hypersensitivity pneumonitis.
Topics: Adrenal Cortex Hormones; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Antineoplastic | 2010 |
A case of lenalidomide-induced hypersensitivity pneumonitis.
Topics: Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersens | 2010 |
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dys | 2007 |